Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study

Zhichao Feng1,2, Jennifer Li3, Shanhu Yao1,2, Qizhi Yu4, Wenming Zhou5, Xiaowen Mao6, Huiling Li1, Wendi Kang1, Xin Ouyang7, Ji Mei8, Qiuhua Zeng9, Jincai Liu10, Xiaqian Ma1,2, Pengfei Rong1,2,*, Wei Wang1,2,*

1Department of Radiology, Third Xiangya Hospital, Central South University, Hunan, China. 2Molecular Imaging Research Center, Central South University, Hunan, China. 3Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. 4Department of Radiology, First Hospital of Changsha, Hunan, China. 5Department of Medical Imaging, First Hospital of Yueyang, Hunan, China. 6Department of Medical Imaging, Central Hospital of Shaoyang, Hunan, China. 7Department of Radiology, Central Hospital of Xiangtan, Hunan, China. 8Department of Radiology, Second Hospital of Changde, Hunan, China. 9Department of Radiology, Central Hospital of Loudi, Hunan, China. 10Department of Radiology, First Affiliated Hospital of University of South China, Hunan, China.

[Received May 27, 2020; Revised June 27, 2020; Accepted June 30, 2020]

ABSTRACT: Coronavirus disease 2019 (COVID-19) is a global pandemic associated with a high mortality. Our study aimed to determine the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19. Consecutive 564 hospitalized patients with confirmed COVID-19 between January 17, 2020 and February 28, 2020 were included in this multicenter, retrospective study. The effects of clinical factors on disease progression and prolonged viral shedding were analyzed using logistic regression and Cox regression analyses. 69 patients (12.2%) developed severe or critical pneumonia, with a higher incidence in the elderly and in individuals with underlying comorbidities, fever, dyspnea, and laboratory and imaging abnormalities at admission. Multivariate logistic regression analysis indicated that older age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02-1.06), hypertension without receiving angiotensinogen converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) therapy (OR, 2.29; 95% CI, 1.14-4.59), and chronic obstructive pulmonary disease (OR, 7.55; 95% CI, 2.44-23.39) were independent risk factors for progression to severe or critical pneumonia. Hypertensive patients without receiving ACEI/ARB therapy showed higher lactate dehydrogenase levels and computed tomography (CT) lung scores at about 3 days after admission than those on ACEI/ARB therapy. Multivariate Cox regression analysis revealed that male gender (hazard ratio [HR], 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were independent factors associated with prolonged viral shedding. Our findings presented several potential clinical factors associated with developing severe or critical pneumonia and prolonged viral shedding, which may provide a rationale for clinicians in medical resource allocation and early intervention.

Key words: Viral pneumonia, coronavirus disease 2019, disease progression, viral shedding, risk factors

The world has witnessed a rapid escalation of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it has become a global pandemic since March 2020 [1].

*Correspondence should be addressed to: Dr. Pengfei Rong (Email: rongpengfei66@163.com) and Dr. Wei Wang (Email: cjr.wangwei@vip.163.com), Third Xiangya Hospital, Central South University, Hunan, China.

Copyright: © 2019 Feng Z et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Many patients who are asymptomatic or experience only mild symptoms have a favorable clinical course and recover soon. However, once it progresses to severe COVID-19 or even a critical stage, patients require more intensive medical resource utilization and have a worse prognosis, with a case fatality rate about 20 times higher than that for non-severe patients [2, 3]. To date, there is no specific anti-coronavirus therapy for severe or critical COVID-19, and whether remdesivir is associated with significant clinical benefits for severe COVID-19 still requires further confirmation [4, 5]. A recent report indicated that early triple antiviral therapy may be helpful in alleviating symptoms and shortening the duration of viral shedding in patients with mild-to-moderate COVID-19 [6]. Thus, the key step in reducing the mortality from COVID-19 should be the prevention of progression from non-severe to severe disease stage and the subsequent development of critical illness. Given the fact that the number of confirmed cases is rapidly growing, and effective medical resource is becoming increasingly scarce, there is an urgent need to identify potential high-risk patients to guide reasonable treatment allocation.

Several reports have proposed that the elderly and patients with chronic comorbidities such as hypertension may be at an increased risk of developing severe COVID-19 pneumonia [7-9]. However, it is currently difficult to distinguish between hypertension as an independent risk factor for the development of severe illness in COVID-19 from one that co-varies with other factors such as age and cardiovascular disease [10]. In addition, there has been considerable interest and debate regarding the risk of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB) therapy in hypertensive patients, presumably through the modulation of the expression of angiotensin converting enzyme 2 (ACE2) [9, 11, 12]. Recent studies have shown that among COVID-19 patients with hypertension, ACEI/ARB use was not associated with an increased risk of mortality compared with ACEI/ARB non-use [13, 14]. However, the potential association between ACEI/ARB use and disease progression remains unclear. In addition, the viral ribonucleic acid (RNA) excretion pattern in respiratory specimens during the treatment of COVID-19 has been analyzed in a limited number of studies, and the factors associated with prolonged viral shedding in COVID-19 patients with different disease severities in large sample population deserve further investigation [15, 16].

Therefore, we conducted this multicenter, retrospective study to determine the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19 in Hunan Province, China.

MATERIALS AND METHODS

Study population

The Institutional Review Board of the Third Xiangya Hospital of Central South University approved our study and waived the need for informed consent because of the retrospective nature of this study. All consecutive adult patients with confirmed COVID-19 who were treated at the Third Xiangya Hospital of Central South University, Changsha Public Health Treatment Center, First Hospital of Yueyang, Junshan People’s Hospital of Yueyang, Central Hospital of Shaoyang, Central Hospital of Xiangtan, Second Hospital of Changde, Central Hospital of Loudi, and First Affiliated Hospital of University of South China between January 17, 2020 and February 28, 2020 were enrolled. Patients without available clinical or imaging data were excluded. The diagnosis of COVID-19 was established on the basis of the World Health Organization interim guidelines, and a confirmed case was defined as positive on the basis of the presence of SARS-CoV-2 RNA on high-throughput sequencing or real-time reverse transcription-polymerase chain reaction (RT-PCR) assay in nasal and pharyngeal swab specimens.

Collection of clinical and imaging data

Data on demographic, epidemiological history, chronic comorbidities, clinical symptoms, and laboratory findings were obtained at admission from electronic medical records. Medication history among individuals with hypertension was recorded, including treatment with ACEIs or ARBs, calcium antagonists, β-blockers, and diuretic agents. Body mass index (BMI) was calculated as weight divided by height squared, and obesity was defined as BMI ≥ 28 kg/m² according to the Chinese-specific cutoffs for general adiposity [17]. All laboratory tests were performed according to the clinical care need of the patient during hospitalization, including complete blood count, assessment of liver and renal function, coagulation testing, and measures of electrolyte, creatine kinase, lactate dehydrogenase (LDH), procalcitonin, and C-reactive protein levels. Respiratory tract specimens were collected daily from patients during the course of hospitalization and tested for SARS-CoV-2 RNA. The treatment protocol for each patient during hospitalization was also recorded, and the exposure of lopinavir/ritonavir was defined as having received at least one dosage of lopinavir/ritonavir treatment. CT images were acquired at admission and at intervals of 3-5 days during hospitalization and were reviewed independently by two experienced radiologists. Typical CT findings for COVID-19 were defined as peripherally distributed multifocal ground-glass opacities (GGOs) with patchy
consolations and a predilection for involvement of the posterior part or lower lobe of the lung [18]. Each of the five lung lobes was reviewed for GGO and consolidation. The extent of the lesions within each lung lobe was semi-quantitatively evaluated by scoring from 0 to 5 based on the degree of involvement, as follows: score 0, no involvement; score 1, ≤ 5% involvement; score 2, 6%-25% involvement; score 3, 26%-50% involvement; score 4, 51%-75% involvement; and score 5, >75% involvement. The total score was calculated by summing the scores of all five lobes to provide a lung CT score ranging from 0 to 25 [19]. The mean values of lung CT scores evaluated by the two radiologists were used for analysis.

Table 1. Clinical and laboratory characteristics of 564 COVID-19 patients according to disease severity.

| Characteristics                      | Total (n = 564) | Severe or critical (n = 69) | Mild or moderate (n = 495) | P     |
|--------------------------------------|----------------|----------------------------|---------------------------|-------|
| Age (years)                          | 47 (36-58)     | 59 (51-66)                 | 45 (35-56)                | < 0.001|
| Male gender                          | 284 (50.4%)    | 39 (56.5%)                 | 245 (49.5%)               | 0.274 |
| Smoking history                      | 47 (8.3%)      | 9 (13.0%)                  | 38 (7.7%)                 | 0.131 |
| Comorbidity                          |                |                            |                           |       |
| Any                                  | 132 (23.4%)    | 37 (53.6%)                 | 95 (19.2%)                | < 0.001|
| Hypertension                         | 82 (14.5%)     | 21 (30.4%)                 | 61 (12.3%)                | < 0.001|
| Diabetes                             | 45 (8.0%)      | 12 (17.4%)                 | 33 (6.7%)                 | 0.002 |
| Cardiovascular disease               | 22 (3.9%)      | 6 (8.7%)                   | 16 (3.2%)                 | 0.002 |
| COPD                                 | 16 (2.8%)      | 9 (13.0%)                  | 7 (1.4%)                  | < 0.001|
| Cerebrovascular disease              | 5 (0.9%)       | 1 (1.5%)                   | 5 (1.0%)                  | 0.878 |
| Chronic renal disease                | 3 (0.5%)       | 2 (2.9%)                   | 1 (0.2%)                  | 0.045 |
| Hepatitis B/C infection              | 9 (1.6%)       | 3 (4.4%)                   | 6 (1.2%)                  | 0.151 |
| Malignancy                           | 4 (0.7%)       | 1 (1.5%)                   | 3 (0.6%)                  | 0.987 |
| Immunodeficiency                     | 1 (0.2%)       | 0 (0)                      | 1 (0.2%)                  | 0.249 |
| Obesity                              | 49 (8.7%)      | 10 (14.5%)                 | 39 (7.9%)                 | 0.068 |
| Symptoms or signs                    |                |                            |                           |       |
| Fever                                | 357 (63.3%)    | 58 (84.1%)                 | 299 (60.4%)               | < 0.001|
| Cough                                | 323 (57.2%)    | 37 (53.6%)                 | 286 (57.8%)               | 0.513 |
| Fatigue                              | 87 (15.4%)     | 8 (11.6%)                  | 79 (16.0%)                | 0.347 |
| Myalgia                              | 25 (4.4%)      | 3 (4.4%)                   | 22 (4.4%)                 | 0.783 |
| Sputum production                    | 51 (9.0%)      | 6 (8.7%)                   | 45 (9.1%)                 | 0.915 |
| Anorexia                             | 26 (4.6%)      | 6 (8.7%)                   | 20 (4.0%)                 | 0.084 |
| Diarrhea                             | 18 (3.2%)      | 4 (5.8%)                   | 14 (2.8%)                 | 0.343 |
| Dyspnea                              | 26 (4.6%)      | 7 (10.1%)                  | 19 (3.8%)                 | 0.019 |
| Hemoglobin, g/L                      | 131 (121-143)  | 131 (119-142)              | 132 (121-144)             | 0.258 |
| Platelet count, x10³/L               | 182 (143-236)  | 163 (138-234)              | 183 (144-237)             | 0.390 |
| Blood leukocyte count, x10³/L        | 4.8 (3.7-6.1)  | 5.6 (3.9-8.3)              | 4.7 (3.6-5.9)             | 0.004 |
| Neutrophil count, x 10³/L            | 3.0 (2.2-4.2)  | 4.4 (2.7-6.8)              | 2.9 (2.2-3.9)             | < 0.001|
| Lymphocyte count, x 10³/L            | 1.1 (0.8-1.5)  | 0.7 (0.5-1.1)              | 1.2 (0.9-1.6)             | < 0.001|
| Alanine aminotransferase, U/L        | 20.3 (15.0-30.4)| 24.7 (16.8-41.0)   | 20.0 (15.0-29.5)          | 0.011 |
| Aspartate aminotransferase, U/L      | 24.3 (19.5-31.5)| 35.0 (25.6-47.0)   | 23.8 (19.0-29.0)          | < 0.001|
| Total bilirubin, µmol/L              | 11.9 (8.7-17.6)| 11.8 (9.0-17.4)           | 11.9 (8.7-17.6)           | 0.887 |
| Albumin, g/L                         | 39.0 (35.7-42.4)| 35.4 (31.7-38.3)   | 39.4 (36.4-42.7)          | < 0.001|
| Blood urea nitrogen, mmol/L          | 4.0 (3.2-5.0)  | 4.9 (3.7-6.2)              | 3.9 (3.1-4.8)             | < 0.001|
| Creatinine, µmol/L                   | 59.0 (46.8-74.0)| 65.1 (53.0-84.0) | 58.2 (46.2-72.9)          | 0.002 |
| Sodium, mmol/L                       | 137.6 (135.4-140.1)| 135.4 (133.3-137.2) | 138.0 (135.9-140.3)       | 0.001 |
| Potassium, mmol/L                    | 4.0 (3.6-4.3)  | 3.9 (3.5-4.3)              | 4.0 (3.6-4.3)             | 0.493 |
| Creatine kinase, U/L                 | 70.8 (48.0-112.8)| 81.7 (48.0-181.2) | 70.0 (48.0-109.3)         | 0.092 |
| Lactate dehydrogenase, U/L           | 189.0 (152.0-244.0) | 304.4 (236.8-378.5) | 183.6 (148.3-230.3)       | < 0.001|
| D-dimer ≥ 0.05 mg/L                  | 269 (47.7%)    | 44 (63.8%)                 | 225 (45.5%)               | 0.004 |
| Procalcitonin ≥ 0.05 ng/L            | 207 (36.7%)    | 38 (55.1%)                 | 169 (34.1%)               | 0.001 |
| C-reactive protein ≥ 10 mg/L         | 286 (50.7%)    | 61 (88.4%)                 | 225 (45.5%)               | < 0.001|
| Abnormal CT findings                 | 516 (91.5%)    | 68 (98.6%)                 | 448 (90.5%)               | 0.025 |
| Lung CT score                        | 6 (4-11)       | 15 (10-21)                 | 6 (3-9)                   | < 0.001|

Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19; 2019 coronavirus disease; CT, computed tomography.

The disease severity of COVID-19 was defined as follows: (1) mild type, with fever or respiratory tract symptoms but without radiological pneumonia; (2) moderate type, with fever, respiratory tract symptoms, and radiological evidence of pneumonia; (3) severe type, with one of the following: a) respiratory distress (respiratory rate ≥ 30 beats/min), b) hypoxia (oxygen saturation ≤ 93% in the resting state), or c) hypoxemia (arterial blood oxygen partial pressure/oxygen concentration ≤ 300mmHg); (4) critical type, with one of
the following: a) respiratory failure requiring mechanical ventilation, b) shock, or c) intensive care unit (ICU) admission because of combined other organ failure.

Duration of viral shedding after illness onset was considered as the number of days from symptom onset to persistent negative results on respiratory tract viral RT-PCR testing. All samples from the same patient were tested until two consecutive samples showed negative results, with the first negative result defining the duration of shedding.

**Statistical Analysis**

Continuous variables are presented as the median and interquartile range (IQR), and categorical variables are presented as frequency and percentage. Differences between groups were analyzed using Student’s t-test or the Mann-Whitney U test for quantitative variables according to the normal distribution and the Chi-square test or Fisher’s exact test for categorical variables. Univariate and multivariate logistic regressions with backward stepwise selection on the basis of the likelihood ratio were used to identify the risk factors for the development of severe or critical pneumonia, and the corresponding odds ratios (ORs) and 95% confidence intervals (CIs) were determined. The cumulative percentage of patients with positive SARS-CoV-2 RNA was calculated using Kaplan Meier curves, and comparisons between groups were performed using the log-rank test. The Cox proportional hazard model was adopted for multivariate analyses of potential risk factors associated with the discontinuation of viral shedding, and the hazard ratio (HR) and 95% CI were calculated. The analyses regarding different factors were based on non-missing data, and missing data were not imputed. All statistical analyses were performed using SPSS statistics software (version 22.0, IBM SPSS Inc., Chicago, IL, USA). A two-sided P value of less than 0.05 was considered statistically significant.

**RESULTS**

**Patient Characteristics**

The study population included 564 adult patients with confirmed COVID-19 from nine hospitals in seven cities (Fig. 1). The clinical characteristics of these patients at admission are presented in Table 1. The median age of patients was 47 years (IQR, 36-58 years; range, 19-84 years), and 284 (50.4%) were men. A total of 132 (23.4%) patients had comorbidities, including hypertension (n = 82 [14.5%]), diabetes (n = 45 [8.0%]), cardiovascular disease (n = 22 [3.9%]), and chronic obstructive pulmonary disease (COPD, n = 16 [2.8%]). There were 49 (8.7%) patients with obesity. The most common self-reported symptoms at onset of illness were fever (n = 357 [63.3%]), cough (n = 323 [57.2%]), fatigue (n = 87 [15.4%]), sputum production (n = 51 [9.0%]), anorexia (n = 26 [4.6%]), and diarrhea (n = 5 [0.9%]).

**Figure 1. The flow chart of the study design.**
[4.6.6%], and dyspnea (n = 26 [4.6%]). A total of 516 (91.5%) patients had typical abnormal findings on chest CT (Fig. 2), with a median lung CT score of 6 (IQR, 4-11; range, 0-25). Sixty-nine of the 564 (12.2%) patients were identified as having severe or critical pneumonia. As summarized in Table 1, these patients were older (P < 0.001) and more likely to have preexisting comorbidities, including hypertension, diabetes, COPD, and chronic renal disease (all P < 0.05), when compared with patients with non-severe disease. Patients who were obese showed a trend towards to develop severe or critical pneumonia though without statistically significance (P = 0.068). The clinical symptoms at illness onset also differed, with those suffering from severe or critical disease more likely to present with fever and dyspnea (both P < 0.05). Furthermore, patients with severe or critical pneumonia had elevated liver enzyme levels (aspartate aminotransferase, P < 0.001), renal dysfunction (blood urea nitrogen, P < 0.001), abnormal coagulation function (D-dimer level ≥ 0.5 mg/L, P = 0.004), increased inflammation-related parameters (LDH, P < 0.001), and a worse lung CT score (P < 0.001). However, lymphocyte count (P < 0.001) was significantly lower in patients with severe or critical pneumonia.

Table 2. Clinical risk factors associated with development of severe or critical illnesses.

| Variables                        | Univariate OR (95% CI) | P value | Multivariate OR (95% CI) | P value |
|----------------------------------|------------------------|---------|--------------------------|---------|
| Age                              | 1.06 (1.04-1.08)       | < 0.001 | 1.04 (1.02-1.07)         | < 0.001 |
| Male gender                      | 1.33 (0.80-2.20)       | 0.275   |                          |         |
| Smoking history                  | 1.80 (0.83-3.92)       | 0.136   |                          |         |
| Hypertension                     | 3.11 (1.75-5.55)       | < 0.001 | 0.064                    |         |
| Diabetes                         | 2.95 (1.44-6.03)       | 0.003   | 0.159                    |         |
| Cardiovascular disease           | 2.85 (1.08-7.56)       | 0.035   | 0.807                    |         |
| COPD                             | 13.81 (4.85-39.38)     | < 0.001 | 7.53 (2.44-23.26)        | < 0.001 |
| Obesity                          | 1.98 (0.94-4.18)       | 0.072   | 0.060                    |         |
| Age                              | 1.06 (1.04-1.08)       | < 0.001 | 1.04 (1.02-1.06)         | < 0.001 |
| Male gender                      | 1.33 (0.80-2.20)       | 0.275   |                          |         |
| Smoking history                  | 1.80 (0.83-3.92)       | 0.136   |                          |         |
| Hypertension                     | < 0.001                |         | 0.046                    |         |
| Non-hypertensive Reference       | Reference              | 1       | Reference                | 1       |
| Hypertensive on ACEI/ARB therapy  | 0.60 (0.08-4.66)       | 0.628   | 0.51 (0.06-3.99)         | 0.517   |
| Hypertensive on other therapy     | 3.93 (2.15-7.19)       | < 0.001 | 2.29 (1.14-4.59)         | 0.020   |
| Diabetes                         | 2.95 (1.44-6.03)       | 0.003   | 0.210                    |         |
| Cardiovascular disease           | 2.85 (1.08-7.56)       | 0.035   | 0.944                    |         |
| COPD                             | 13.81 (4.85-39.38)     | < 0.001 | 7.55 (2.44-23.39)        | < 0.001 |
| Obesity                          | 1.98 (0.94-4.18)       | 0.072   | 0.086                    |         |

Factors associated with the development of severe or critical COVID-19

To investigate the clinical risk factors for the development of severe or critical pneumonia in COVID-19 patients, univariate and multivariate logistic regression analyses were performed (Table 2). Univariate analysis identified age, hypertension, diabetes, cardiovascular disease, and COPD to be associated with the development of severe or critical pneumonia (all P < 0.05), while only older age (OR, 1.04; 95% CI, 1.02-1.07; P < 0.001) and COPD (OR, 7.53; 95% CI, 2.44-23.26; P < 0.001) were identified as independent risk factors in multivariate analysis. Furthermore, after stratification according to whether patients with hypertension were receiving ACEI/ARB therapy or not, the presence of hypertension without receiving ACEI/ARB therapy became independently associated with the development of severe or critical pneumonia (OR, 2.29; 95% CI, 1.14-4.59; P = 0.020). Compared with patients without hypertension, hypertension on ACEI/ARB therapy was not associated with the development of severe or critical pneumonia (OR, 0.51; 95% CI, 0.06-3.99; P = 0.517). Besides, subgroup analyses according to age or gender showed that hypertension without receiving ACEI/ARB therapy and COPD remained significantly associated with disease progression only among the older patients (age ≥ 50 years), and only older age was significantly associated with disease progression for both male and female patients (Supplementary Table 1-2).
**ACEI/ARB therapy in patients with hypertension**

In our cohort, 82 individuals were recorded as having hypertension and only 16 were on ACEI/ARB therapy (including 6 patients receiving ARB monotherapy, 9 receiving combined ARB and calcium antagonist, and 1 receiving AECI monotherapy). There were 49 patients on non-ACEI/ARB antihypertensive therapy (including 39 patients receiving calcium antagonist monotherapy, 3 receiving β-blocker monotherapy, 2 receiving diuretic monotherapy, and 5 receiving combined calcium antagonist and β-blocker therapy), and all were maintained on their usual antihypertensive regimen during hospitalization. The remaining 17 patients were not on antihypertensive medications or had unavailable data and received amlodipine or nitrendipine to control blood pressure during hospitalization as necessary. As summarized in Table 3, hypertensive patients on ACEI/ARB therapy had similar baseline clinical characteristics and laboratory findings as those on non-ACEI/ARB therapy. However, in contrast with those on ACEI/ARB therapy, patients who were not receiving ACEI/ARB therapy were more likely to develop severe or critical pneumonia ($P = 0.037$). Laboratory and imaging data from 65 patients with hypertension during hospitalization were analyzed (Figure 3), showing that, at about 3 days after admission, LDH levels and CT lung scores were higher in patients who were not receiving ACEI/ARB therapy than in those on ACEI/ARB therapy.

Table 3. Comparison between hypertensive patients on ACEI/ARB therapy and on non-ACEI/ARB therapy ($n = 65$).

| Characteristics              | ACEI/ARB (n = 16) | Non-ACEI/ARB (n = 49) | $P$  |
|-----------------------------|------------------|-----------------------|------|
| Age (years)                 | 57 (51-65)       | 63 (53-69)            | 0.106|
| Male gender                 | 10 (62.5%)       | 23 (46.9%)            | 0.280|
| Smoking history             | 2 (12.5%)        | 5 (10.2%)             | 0.836|
| Comorbidity                 |                  |                       |      |
| Diabetes                    | 2 (12.5%)        | 18 (36.7%)            | 0.131|
| Cardiovascular disease      | 0 (0)            | 8 (16.3%)             | 0.198|
| COPD                        | 0 (0)            | 1 (2.0%)              | 0.553|
| Cerebrovascular disease     | 0 (0)            | 3 (6.1%)              | 0.311|
| Chronic renal disease       | 1 (6.3%)         | 1 (2.0%)              | 0.435|
| Hepatitis B infection       | 0 (0)            | 2 (4.1%)              | 0.412|
| Obesity                     | 1 (6.3%)         | 10 (20.4%)            | 0.354|
| Medication history          |                  |                       |      |
| Aspirin                     | 0 (0)            | 3 (6.1%)              | 0.311|
| Statins                     | 1 (6.3%)         | 2 (4.1%)              | 0.743|
| Metformin                   | 1 (6.3%)         | 8 (16.3%)             | 0.551|
| Other oral hypoglycemic agents | 1 (6.3%)     | 10 (20.4%)            | 0.354|
| Insulin                     | 0 (0)            | 2 (4.1%)              | 0.412|
| Systolic pressure, mmHg     | 132 (120-137)    | 136 (120-146)         | 0.107|
| Diastolic pressure, mmHg    | 80 (71-89)       | 80 (78-87)            | 0.547|
### Hemoglobin, g/L
- 133 (125-150)
- 133 (118-138)

### Platelet count, ×10⁹/L
- 181 (135-241)
- 182 (147-239)

### Neutrophil count, ×10⁹/L
- 5.5 (4.6-6.5)
- 5.2 (3.9-7.0)

### Lymphocyte count, ×10⁹/L
- 1.1 (0.9-1.4)
- 1.0 (0.7-1.5)

### Alanine aminotransferase, U/L
- 28.9 (16.2-40.7)
- 23.0 (17.2-31.5)

### Aspartate aminotransferase, U/L
- 25.0 (20.0-30.9)
- 26.3 (20.0-36.3)

### Total bilirubin, μmol/L
- 12.6 (10.3-19.9)
- 12.5 (9.5-19.0)

### Albumin, g/L
- 38.4 (34.6-44.5)
- 37.0 (32.2-40.4)

### Blood urea nitrogen, mmol/L
- 4.8 (4.1-5.8)
- 4.5 (3.7-6.5)

### Creatinine, μmol/L
- 64.7 (44.9-82.1)
- 63.3 (51.2-78.7)

### Sodium, mmol/L
- 136.3 (134.7-137.2)
- 137.5 (134.6-140.6)

### Potassium, mmol/L
- 4.0 (3.6-4.4)
- 3.9 (3.5-4.2)

### Creatine kinase, U/L
- 118.5 (64.6-187.3)
- 64.5 (46.5-147.2)

### Lactate dehydrogenase, U/L
- 184.0 (157.1-281.7)
- 238.0 (164.1-315.2)

### D-dimer ≥ 0.05 mg/L
- 10 (62.5%)
- 27 (55.1%)

### Procalcitonin ≥ 0.05 ng/L
- 6 (37.5%)
- 27 (55.1%)

### C-reactive protein ≥ 10 mg/L
- 11 (68.8%)
- 41 (83.7%)

### Abnormal CT findings
- 15 (93.8%)
- 46 (93.9%)

### Lung CT score
- 7 (3-14)
- 10 (5-16)

### Combined treatments after admission
- **Antiviral therapy**
  - 15 (93.8%)
  - 45 (91.8%)
- **Interferon α**
  - 8 (50.0%)
  - 35 (71.4%)
- **Intravenous antibiotics**
  - 12 (75.0%)
  - 34 (69.4%)
- **Severe or critical illnesses**
  - 1 (6.3%)
  - 16 (32.7%)

### Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; COPD, chronic obstructive pulmonary disease; CT computed tomography.

---

**Factors associated with prolonged viral shedding**

The median duration of viral shedding of all patients, patients with severe or critical disease, and patients with mild or moderate disease were 19 days, 21 days, and 19 days, respectively (Fig. 4). Univariate Cox regression analysis showed that older age (P = 0.032), any comorbidity (P = 0.028), severe or critical illnesses (P = 0.002), receiving lopinavir/ritonavir treatment within 7 days from illness onset (P = 0.013), receiving systemic glucocorticoid therapy (P<0.001), and invasive mechanical ventilation (P = 0.011) were found to be significantly associated with the duration of viral shedding in patients with COVID-19 (Table 4). In the multivariate analysis, male gender (HR, 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were identified to be independently associated with prolonged viral shedding.

---

**Figure 3. Dynamic profile of laboratory and imaging findings between hypertensive patients on ACEI/ARB therapy and those on non-ACEI/ARB therapy.** Timeline bar graphs illustrate the laboratory (A) and imaging (B) parameters in 65 patients based on the days after admission. *P < .05 for patients on ACEI/ARB therapy vs patients on non-ACEI/ARB therapy.
Table 4. Clinical risk factors associated with prolonged viral shedding.

| Variables                                      | Univariate HR (95% CI) | P value | Multivariate HR (95% CI) | P value |
|------------------------------------------------|------------------------|---------|--------------------------|---------|
| Age                                            | 1.01 (1.00-1.01)       | 0.032   | 0.770                    |         |
| Male gender                                    | 1.15 (0.97-1.39)       | 0.102   | 1.22 (1.02-1.46)         | 0.030   |
| Smoking history                                | 0.83 (0.60-1.12)       | 0.227   |                          |         |
| Any comorbidity                                | 1.25 (1.02-1.54)       | 0.028   | 0.202                    |         |
| Hypertension                                   | 0.106                  | 0.010   | 0.502                    |         |
| Non-hypertensive                               | Reference              | 1       |                          | 1       |
| Hypertensive on AECI/ARB therapy               | 0.63 (0.37-1.08)       | 0.095   |                          | 0.383   |
| Hypertensive on other therapy                  | 0.82 (0.62-1.08)       | 0.159   |                          | 0.485   |
| Diabetes                                       | 0.99 (0.72-1.39)       | 0.976   |                          |         |
| Cardiovascular disease                         | 1.29 (0.82-2.02)       | 0.268   |                          |         |
| COPD                                           | 0.74 (0.44-1.24)       | 0.248   |                          |         |
| Obesity                                        | 1.23 (0.90-1.69)       | 0.197   |                          |         |
| Severe or critical illnesses                   | 1.52 (1.16-1.96)       | 0.002   | 0.340                    |         |
| Lopinavir/ritonavir treatment within 7 days from illness onset | 0.80 (0.67-0.95) | 0.013   | 0.75 (0.63-0.90)         | 0.002   |
| Systematic glucocorticoid therapy              | 1.67 (1.35-2.04)       | < 0.001 | 1.79 (1.46-2.21)         | < 0.001 |
| Invasive mechanical ventilation                | 1.96 (1.16-3.23)       | 0.011   | 0.877                    |         |

Abbreviations: AECI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.

Kaplan Meier curves between male and female patients (log-rank P = 0.093), between patients who received lopinavir/ritonavir treatment within 7 days from illness onset and those who did not (log-rank P = 0.009), and between patients who received systematic glucocorticoid therapy and those who did not (log-rank P < 0.001) are shown in Figure 4. Further stratification analysis showed that male gender (HR, 1.21; 95% CI, 1.00-1.47), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.76; 95% CI, 0.62-0.92), and receiving systemic glucocorticoid therapy (HR, 1.69; 95% CI, 1.32-2.17) remained independently associated with prolonged viral shedding only in patients with mild or moderate COVID-19, while among those with severe or critical COVID-19, older age (HR, 1.04; 95% CI, 1.02-1.06) and receiving systemic glucocorticoid therapy (HR, 1.85; 95% CI, 1.05-3.26) were confirmed to be independently associated with prolonged viral shedding (Table 5).

Figure 4. Duration of SARS-CoV-2 viral shedding by disease severity. The white dots represent medians, the black bars represent interquartile ranges, and the thin black lines represent upper and lower adjacent values. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
DISCUSSION

In this study, we described the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19. Our results showed that older age, hypertension without receiving ACEI/ARB therapy, and COPD were independent risk factors for progression to severe or critical pneumonia. In addition, male gender, receiving lopinavir/ritonavir treatment within 7 days from illness onset, and receiving systemic glucocorticoid therapy were found to be associated with prolonged viral shedding in COVID-19 patients.

Table 5. Clinical risk factors associated with prolonged viral shedding according to disease severity.

| Variables                                      | Severe or critical |           | Mild or moderate |           |
|------------------------------------------------|--------------------|-----------|------------------|-----------|
| Age                                            | 1.04 (1.02-1.06)    | 0.001     | 0.362            |           |
| Male gender                                    | 0.481              | 1.21 (1.00-1.47) | 0.049     |           |
| Smoking history                                | 0.445              | 0.473     | 0.506            |           |
| Any comorbidity                                | 0.924              | 0.577     | 0.506            |           |
| Hypertension                                   | 0.535              | 1         | 1                |           |
| Non-hypertensive                               | 1                  | 1         | 1                |           |
| Hypertensive on ACEI/ARB therapy               | 0.955              | 0.299     | 0.299            |           |
| Hypertensive on other therapy                  | 0.266              | 0.824     | 0.824            |           |
| Diabetes                                       | 0.888              | 0.663     | 0.663            |           |
| Cardiovascular disease                         | 0.121              | 0.292     | 0.292            |           |
| COPD                                           | 0.499              | 0.894     | 0.894            |           |
| Obesity                                        | 0.813              | 0.174     | 0.174            |           |
| Lopinavir/ritonavir treatment within 7 days from illness onset | 0.414    | 0.76 (0.62-0.92) | 0.005     |           |
| Systematic glucocorticoid therapy              | 1.85 (1.05-3.26)    | 0.034     | 1.69 (1.32-2.17) | 0.001     |
| Invasive mechanical ventilation                | 0.409              |           |                  |           |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio.

Consistent with the clinical experience around the world, our cohort study also confirmed that older age was independently associated with disease progression in patients with COVID-19. The association between age and disease progression may be attributed to the accumulation of medical comorbidities with age or a decline in immune function over time [20]. Previous data were not adjusted for confounding factors of age and other comorbidities to definitively show whether hypertension was independently associated with worse outcomes [7, 8]. Given the close association between age and hypertension, our study adjusted for age and revealed that...
hypertension was not an independent risk factor for disease progression. Consistent with a recent report, COPD was also found to predispose COVID-19 patients to adverse clinical outcomes, which may be explained by the insufficiency of pulmonary function reserve capacity [21]. Besides, our results showed patients who were obese had a trend towards developing severe or critical pneumonia, but obesity was not confirmed as an independent risk factor associated with progression by multivariate analysis. Though these findings were slightly inconsistent with previous reports, obese patients with COVID-19 should be paid more attention in aggressive management to prevent progression [22, 23].

We further performed stratification analysis for hypertension according to whether receiving ACEI/ARB antihypertensive therapy and revealed that among patients with hypertension, only those who were not receiving ACEI/ARB therapy had a higher risk of developing severe or critical pneumonia, although we acknowledged that the analysis was conducted within a limited sample size - with only 16 of 82 patients on ACEI/ ARB therapy. The dynamic profile of laboratory and imaging findings showed that LDH levels and CT lung scores were higher among patients without receiving ACEI/ARB therapy than among those on ACEI/ARB therapy, at about 3 days after admission. Damage to the liver, kidney, or lung in severe or critical COVID-19 attacks may contribute to cellular death and LDH leakage, consequently increasing serum LDH levels, while CT lung score is a semi-quantitative index associated with lung involvement [20, 24]. These dynamic results indicated that hypertensive patients without receiving ACEI/ARB therapy had more severe multiple organ damage peaks, which made them more susceptible to severe or critical pneumonia.

COVID-19 patients with hypertension may have worse outcomes due to decreased ACE2 levels. ACE2 is highly expressed in both the lung and myocardium and converts angiotensin II (AII) into angiotensin 1-7, which can downregulate ACE and directly cause vasodilatation [25-27]. It has been proposed that the binding of the SARS-CoV-2 spike glycoprotein (S-protein) to the functional receptor ACE2 results in proteolytic cleavage by type II transmembrane serine proteases (TMPRSS2) [28-30]. Downregulation of ACE2 levels has also been shown in hypertensive animal models, although there has been limited success in translational confirmation in human studies [31, 32]. None the less, this may be exacerbated by the further reduction in available ACE2 following coronavirus infection. Both SARS-CoV and SARS-CoV-2 can gain entry into the host cell through binding of the S-protein to the membrane-bound ACE2 aminopeptidase, which is then cleaved by serine proteases to allow for membrane fusion and invasion [30, 33]. Following infection, there is a reduction in pulmonary ACE2, either through internalization with viral entry and/or downregulation of ACE2 enzyme during this process. Hence, this may exacerbate the lower baseline ACE2 function in hypertensive patients, leading to the accumulation of AII and reduced angiotensin 1-7, and subsequently worse immune-related cytolysis and lung injury, which was validated by the linear association between elevated plasma AII levels and viral load or lung injury in COVID-19 patients [34].

The use of ACEI or ARB likely promotes feedback upregulation of ACE2 expression in hypertension, although animal studies have found either no effect or even downregulation of ACE2 levels in the context of cardiovascular disease with ACEI/ARB therapy [27, 35-37]. Nonetheless, this may explain our finding that ACEI/ARB therapy may be protective against severe infection. Further evidence that would support this hypothesis comes from earlier studies in which ACEI/statins were protective against severe pneumonia, recombinant ACE2 protected mice from lung injury following SARS-CoV infection, and ARBs reduced acute lung injury in rats injected with SARS-CoV S-protein [38, 39].

As can be seen from our results, patients who had received systemic glucocorticoid therapy had a longer duration of viral RNA shedding than did those who did not. Glucocorticoid treatment might efficiently inhibit T-cell-mediated immune response, thus reducing the ability of the body to clear the virus. Several previous studies have reported that corticosteroid therapy is linked to persistent viral RNA shedding in patients with MERS and SARS [40, 41]. Xu et al also showed that corticosteroid use was related to prolonged viral shedding, but this was not found to be an independent risk factor in the multivariable model [16]. Nevertheless, our results showed that systemic glucocorticoid therapy was independently associated with prolonged duration of viral shedding in patients with COVID-19 regardless of disease severity. In addition, among the non-severe COVID-19 patients, female individuals and patients who had received lopinavir/ritonavir treatment early showed shorter duration of viral shedding. Recent reports showed that early antiviral treatment could shorten SARS-CoV-2 viral shedding duration in patients with COVID-19 [42, 43]. Our results further confirmed the significance of early antiviral treatment only in non-severe patients, and a recent randomized controlled trial also indicated that lopinavir-ritonavir treatment was not associated with clinical benefits, including viral shedding, in patients with severe COVID-19 [44]. Nevertheless, further clinical trials on the effects of early administration of lopinavir-ritonavir in patients with non-severe COVID-19 remain needed. The sex-related difference in duration of viral RNA shedding was consistent with the findings of a
previous report, and this phenomenon may be explained by sex-specific immune responses related to sex hormones or ACE2 expression [16]. Females are deemed to have stronger immune system responses than males, as they exhibit lower infection and mortality rates when faced with infectious diseases, and they also show higher responses to various vaccinations than do males [45]. Therefore, our findings have been added to the existing literature regarding viral RNA excretion patterns in patients with COVID-19 based on larger sample sizes.

There were several limitations to this study. First, our study was conducted using a retrospective data analysis. Second, given the variation in the clinical management among different hospitals, some cases had incomplete laboratory test results. All data generation was clinically driven and not systematic. Third, most patients had recovered and been discharged at the time of data analysis and only 3 patients died during admission, so the clinical factors associated with fatal outcomes and the difference of mortality rates in specific sub-populations could not be analyzed. Fourth, there was a limited number of hypertensive patients who received ACEI or ARB therapy, and we could not analyze the effect of AECI and ARB individually. A larger cohort study of COVID-19 patients with hypertension from other cities in China and other countries would help to further validate the potential effect of AECI/ARB therapy.

COVID-19 is a fast-evolving, global pandemic with a higher risk of severe or critical illnesses in individuals who are older, have underlying hypertension without receiving ACEI/ARB therapy, or have COPD. In addition, male gender, receiving lopinavir/ritonavir treatment early, and receiving systemic glucocorticoid therapy were independently associated with prolonged viral shedding. These findings may provide a rationale to clinicians for the risk stratification, medical resource allocation, and early intervention.

Acknowledgements

We thank Hongzhuan Tan, from the Department of Epidemiology, Xiangya School of Public Health, Central South University for his kind support and advice in statistical analysis. We also thank Wei Nie, Qin Liu, Jing Zhao, Junhong Duan, Zhimin Yan, and Min Yang, from Department of Radiology, Ying Li, from Health Management Center, Sujie Jia, from Department of Pharmacy, Third Xiangya Hospital, Central South University, for their help in data collection and analysis. They were not compensated for their contributions. This study was supported by National Natural Science Foundation of China (81771827, 81471715).

Conflict of Interest Disclosures

The authors declare that they have no competing interests.

Supplementary Materials

The Supplementation data can be found online at: [www.aginganddisease.org](http://www.aginganddisease.org).

References

[1] Wu Z, McGoogan JM (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 10.1001/jama.2020.2648;10.1001/jama.2020.2648.

[2] Chen N, Zhou M, Dong X, et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England), 395:507-513.

[3] Yang Y, Lu Q, Liu M, et al. (2020). Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 10.1101/2020.02.10.20021675 %J medRxiv:2020.02.10.20021675.

[4] Wang Y, Zhang D, Du G, et al. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England), 395:1569-1578.

[5] Grein J, Ohmagari N, Shin D, et al. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med, 382:2327-2336.

[6] Hung IF-N, Lung K-C, Tso EY-K, et al. (2020). Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet, 395:1695-1704.

[7] Wang D, Hu B, Hu C, et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 10.1001/jama.2020.1585.

[8] Guan WJ, Ni ZY, Hu Y, et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 382:1708-1720.

[9] Fang L, Karakulakis G, Roth M (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med, 8:e21.

[10] Cook TM (2020). The importance of hypertension as a risk factor for severe illness and mortality in COVID-19. Anaesthesia, 75:976-977.

[11] Kuster GM, Pfister O, Burkard T, et al. (2020). SARSCoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J, 41:1801-1803.
[12] Peng YD, Meng K, Guan HQ, et al. (2020). [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua xin xue guan bing za zhi, 48: E004.

[27] Ocairan MP, Godoy I, Jalil JE, et al. (2006). Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension, 48:572-578.

[28] Zhou P, Yang XL, Wang XG, et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579:270-273.

[29] Wrapp D, Wang N, Corbett KS, et al. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367:1260-1263.

[30] Hoffmann M, Kleine-Weber H, Schroeder S, et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181:271-280 e278.

[31] Crackower MA, Sarao R, Oudit GY, et al. (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 417:822-828.

[32] Mendoza-Torres E, Oyarzun A, Mondaca-Ruff D, et al. (2015). ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis, 9:217-237.

[33] de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016). SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 14:523-534.

[34] Liu Y, Yang Y, Zhang C, et al. (2020). Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life sciences, 63:364-374.

[35] Agata J, Ura N, Yoshida H, et al. (2006). Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res, 29:865-874.

[36] Burrell LM, Risvans J, Kubota E, et al. (2005). Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J, 26:369-375; discussion 322-364.

[37] Ferrario CM, Jessup J, Chappell MC, et al. (2005). Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 111:2605-2610.

[38] Mortensen EM, Pugh MJ, Copeland LA, et al. (2008). Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J, 31:611-617.

[39] Imair Y, Kuba K, Rao S, et al. (2005). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436:112-116.

[40] Arabi YM, Mandourah Y, Al-Hameed F, et al. (2018). Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med, 197:757-767.

[41] Lee N, Allen Chan KC, Hui DS, et al. (2004). Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol, 31:304-309.

[42] Yan D, Liu XY, Zhu YN, et al. (2020). Factors associated with prolonged viral shedding and impact of angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the ATI-ERK/p38 MAP kinase pathway. Am J Pathol, 172:1174-1183.
Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J. 10.1183/13993003.00799-2020:2000799.

Fu Y, Han P, Zhu R, et al. (2020). Risk Factors for Viral RNA Shedding in COVID-19 Patients. European Respiratory Journal. 10.1183/13993003.01190-2020:2001190.

Cao B, Wang Y, Wen D, et al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 382:1787-1799.

Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B (2015). How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell, 14:309-321.